Adicet Bio
ACET
107 hedge funds and large institutions have $231M invested in Adicet Bio in 2023 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 25 increasing their positions, 32 reducing their positions, and 18 closing their positions.
494% more call options, than puts
Call options by funds: $1.1M | Put options by funds: $186K
56% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 18
8% more funds holding
Funds holding: 99 → 107 (+8)
0.18% less ownership
Funds ownership: 6.03% → 5.86% (-0.18%)
22% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 32
37% less capital invested
Capital invested by funds: $370M → $231M (-$138M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carlyle Group
Washington,
District of Columbia
|
+$16.6M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$15.1M |
| 3 |
Renaissance Technologies
New York
|
+$2.24M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.63M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$13.5M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.36M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5.11M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.41M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.37M |
ACET Hedge Fund Activity: Q1 2023 in Review
107 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q1 2023, worth a combined $231M — down 37% from $370M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ACET positions and 18 closed out — a net gain of 10 holders — while 25 added to existing stakes and 32 trimmed.
The largest buyer was Carlyle Group, opening a new position worth an estimated $16.6M. The largest seller was State Street, cutting an estimated $13.5M.
- 107 institutional investors held Adicet Bio (ACET) as of Q1 2023, up from 99 in Q4 2022.
- Funds reported $231M of Adicet Bio stock for Q1 2023, down 37% quarter-over-quarter.
- 28 funds opened new Adicet Bio positions in Q1 2023 and 18 closed out, a net change of +10 holders.
- The largest Adicet Bio buyer in Q1 2023 was Carlyle Group, an estimated $16.6M added.
- The largest Adicet Bio seller in Q1 2023 was State Street, an estimated $13.5M sold.
Based on aggregated 13F filings for Q1 2023.